tiprankstipranks
Trending News
More News >
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
Australian Market

Chimeric Therapeutics Ltd. (CHM) AI Stock Analysis

Compare
10 Followers

Top Page

AU

Chimeric Therapeutics Ltd.

(Sydney:CHM)

Rating:42Neutral
Price Target:
Chimeric Therapeutics Ltd. shows strong revenue growth potential but faces significant challenges in profitability and cash flow generation, impacting its financial performance score. The absence of technical indicators limits the technical analysis, and a negative P/E ratio adversely affects the valuation score. Overall, the company's financial restructuring is crucial for enhancing its stock performance in the biotechnology industry.

Chimeric Therapeutics Ltd. (CHM) vs. iShares MSCI Australia ETF (EWA)

Chimeric Therapeutics Ltd. Business Overview & Revenue Model

Company DescriptionChimeric Therapeutics Ltd. (CHM) is a biotechnology company focused on the development of novel cell therapies for cancer treatment. The company leverages its expertise in chimeric antigen receptor T-cell (CAR-T) technology to design and develop next-generation therapies aimed at improving patient outcomes. Chimeric Therapeutics is committed to pioneering advanced approaches in immunotherapy, with a pipeline of products targeting various cancer indications.
How the Company Makes MoneyChimeric Therapeutics makes money primarily through the development and commercialization of its CAR-T cell therapy products. The company's revenue streams include licensing agreements, where it partners with other pharmaceutical companies to co-develop or market its therapies. Additionally, Chimeric Therapeutics may receive milestone payments and royalties from these partnerships as their products advance through clinical trials and reach the market. Furthermore, the company might engage in research collaborations and secure grants or funding from governmental or non-governmental organizations, contributing to its financial resources.

Chimeric Therapeutics Ltd. Financial Statement Overview

Summary
Chimeric Therapeutics Ltd. exhibits strong revenue growth, with a 65.5% increase from 2023 to 2024. However, the company struggles with profitability, as indicated by negative net profit and EBIT margins. The balance sheet shows strong equity relative to assets, with no debt, but declining equity and increasing liabilities pose risks. Cash flow management has improved with positive free cash flow in 2024, but operating cash flow remains negative, underscoring challenges in cash generation from operations.
Income Statement
40
Negative
Chimeric Therapeutics Ltd. demonstrates a consistent increase in revenue over the years, highlighted by a significant revenue growth rate of 65.5% from 2023 to 2024. However, the company struggles with profitability, as indicated by negative net profit and EBIT margins across all periods. The gross profit margin improved significantly in 2024, but the overall loss-making position impacts the score negatively.
Balance Sheet
55
Neutral
The balance sheet shows a strong equity position relative to assets, with an equity ratio of 16.2% as of 2024 despite declining from previous years. The absence of debt is a positive factor, but the shrinking equity and increasing liabilities pose potential risks. Return on equity is negative due to the net losses, impacting the overall score.
Cash Flow
45
Neutral
The company shows improvement in cash flow management with a positive free cash flow in 2024, a significant turnaround from prior periods. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is unfavorable, emphasizing challenges in cash generation from operations.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
3.80M7.46M4.51M2.62M2.65K0.00
Gross Profit
3.32M7.45M3.54M1.67M-844.31K0.00
EBIT
-14.17M-12.31M-29.49M-13.82M-15.11M-64.01K
EBITDA
-14.50M-11.30M-24.02M-13.62M-14.00M0.00
Net Income Common Stockholders
-17.83M-12.53M-25.92M-14.62M-15.11M-64.01K
Balance SheetCash, Cash Equivalents and Short-Term Investments
3.63M3.05M5.37M18.38M22.41M100.00
Total Assets
22.52M15.27M22.38M34.88M36.50M100.00
Total Debt
0.000.000.000.000.0034.01K
Net Debt
-3.63M-3.05M-5.37M-18.38M-22.41M33.91K
Total Liabilities
6.56M12.80M16.71M9.17M11.37M64.01K
Stockholders Equity
15.95M2.47M5.66M25.71M25.13M-63.91K
Cash FlowFree Cash Flow
274.83K10.11K-16.43M-13.69M-14.15M-34.01K
Operating Cash Flow
-5.51M-7.54M-16.32M-13.15M-8.84M-34.01K
Investing Cash Flow
2.52K0.00-112.19K-564.88K-5.30M0.00
Financing Cash Flow
6.98M8.26M263.68K9.50M36.54M34.11K

Chimeric Therapeutics Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURAC
54
Neutral
AU$205.88M-37.20%32.02%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
AUCHM
42
Neutral
AU$10.08M-180.09%28.57%
AUIMU
41
Neutral
$119.47M-99.05%-34.09%
AUBIT
36
Underperform
$3.32M-119.28%64.10%
AUOPT
30
Underperform
AU$738.77M
-24.46%-7.90%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CHM
Chimeric Therapeutics Ltd.
0.01
-0.01
-50.00%
AU:OPT
Opthea
0.60
0.15
34.53%
AU:BIT
Biotron
0.01
-0.04
-78.00%
AU:IMU
Imugene Limited
0.02
-0.04
-72.41%
AU:RAC
Race Oncology Ltd.
1.18
-0.72
-37.89%

Chimeric Therapeutics Ltd. Corporate Events

Chimeric Therapeutics Announces Change in Substantial Shareholding
May 1, 2025

Chimeric Therapeutics Ltd announced a change in the substantial holding of its shares, with Paul Hopper’s voting power decreasing from 12.4% to 11.3%. This change was due to Deborah Coleman’s participation in an entitlement offer, which affected 10 million shares. The announcement highlights shifts in shareholder dynamics, potentially impacting the company’s governance and strategic decisions.

Chimeric Therapeutics Director Increases Stake Through Entitlement Offer
May 1, 2025

Chimeric Therapeutics Limited has announced a change in the director’s interest, with Paul Hopper acquiring an additional 10 million shares and 10 million options indirectly through participation in an entitlement offer. This change reflects a strategic move by the company to strengthen its financial position and potentially enhance its market presence, impacting stakeholders by increasing the director’s stake in the company.

Chimeric Therapeutics Director Increases Stake Through Entitlement Offer
May 1, 2025

Chimeric Therapeutics Limited announced a change in the director’s interest, with Phillip Hains acquiring an additional 2,608,696 ordinary shares and the same number of options through participation in an entitlement offer. This change reflects the company’s ongoing efforts to strengthen its financial position and enhance shareholder value, potentially impacting its market presence and stakeholder interests.

Chimeric Therapeutics Issues New Securities to Bolster R&D
Apr 30, 2025

Chimeric Therapeutics Ltd. has announced the issuance of 197,203,052 securities under an Entitlement Offer, as per the prospectus dated March 18, 2025. This move is part of the company’s strategy to enhance its financial position and support its ongoing research and development efforts in the field of cancer therapeutics.

Chimeric Therapeutics Expands CHM CDH17 Clinical Trial to Emory Winship Cancer Institute
Apr 24, 2025

Chimeric Therapeutics has announced that the Emory Winship Cancer Institute in Atlanta, Georgia, has joined its Phase 1/2 clinical trial for CHM CDH17, a novel CAR-T cell therapy targeting CDH17, a biomarker linked to poor prognosis in gastrointestinal tumors. This milestone marks the opening of the fourth and final clinical trial site in the USA, demonstrating Chimeric’s commitment to advancing cell therapy and enhancing its value to patients and shareholders.

Chimeric Therapeutics Completes $1 Million Entitlement Offer to Advance Cancer Therapies
Apr 24, 2025

Chimeric Therapeutics has completed its entitlement offer, raising approximately $1 million through the issuance of new shares and options, though a shortfall of $2.2 million remains. The funds will support the company’s ongoing cell therapy programs, with trading of the new shares and options set to commence on 1 May 2025. The entitlement offer reflects continued shareholder support and positions Chimeric to further its innovative cancer treatment initiatives.

Chimeric Therapeutics Advances CAR-T Trials with New Collaborations and Funding
Apr 23, 2025

Chimeric Therapeutics announced significant progress in its clinical trials for the quarter ending March 31, 2025. The CHM CORE-NK studies have advanced with patient recruitment and dosing at prominent U.S. cancer centers, while the CHM CDH17 CAR-T trial, targeting advanced cancers, has expanded to include the University of Chicago Medicine. This trial is notable for its pioneering approach as the first anti-CDH17-directed CAR-T therapy, showing promising preclinical results. The company also secured $4 million in non-dilutive funding to support these developments, indicating strong financial backing and potential for impactful advancements in cancer treatment.

Chimeric Therapeutics Lists Options on ASX to Boost Market Engagement
Apr 3, 2025

Chimeric Therapeutics Ltd. has announced that its previously unlisted options, issued under the ASX code CHMAAC, are now listed on the ASX under the code CHMO. This move allows option holders to trade these options on the ASX, aligning with the company’s recent non-renounceable pro-rata entitlement offer. The listing does not change the number or terms of the options, and the entitlement offer is set to close on 22 April 2025. This development is expected to enhance the liquidity and accessibility of the company’s options, potentially benefiting stakeholders by increasing market engagement and investment opportunities.

Chimeric Therapeutics Extends Entitlement Offer Deadline
Apr 2, 2025

Chimeric Therapeutics Limited has announced an extension of the closing date for its non-renounceable entitlement offer to 22 April 2025. This extension provides shareholders with additional time to participate in the offer, potentially impacting the company’s capital structure and shareholder base. The offer includes the opportunity for eligible shareholders to apply for additional shares under a Top Up Facility, which could enhance shareholder value and support the company’s ongoing development of its cell therapy portfolio.

Chimeric Therapeutics Announces Shareholder Structure Analysis
Apr 1, 2025

Chimeric Therapeutics Ltd. has released an analysis of its holdings, revealing that 157 holders collectively own 624,999,999 units, representing 100% of the company’s shares. The largest shareholder, Deborah Anne Coleman, holds 12.8% of the total securities. This distribution of holdings reflects the company’s shareholder structure and could influence future strategic decisions and investor relations.

Chimeric Therapeutics Announces New ASX Quotation for Options
Apr 1, 2025

Chimeric Therapeutics Ltd. has announced the quotation of a new class of options on the Australian Securities Exchange (ASX), with 624,999,999 options expiring on December 19, 2025, at an exercise price of $0.008. This move is expected to enhance the company’s capital structure, potentially providing additional funding for its ongoing research and development efforts in the field of cancer immunotherapy, thereby strengthening its position in the biotechnology sector.

Chimeric Therapeutics Launches $3.2 Million Entitlement Offer
Mar 25, 2025

Chimeric Therapeutics has announced the opening of its Entitlement Offer, which aims to raise approximately $3.2 million. This offer, which includes a non-renounceable pro rata entitlement of new shares and options, is expected to impact the company’s financial standing and market positioning positively.

Chimeric Therapeutics Announces Proposed Issue of 25 Million Securities
Mar 18, 2025

Chimeric Therapeutics Ltd. has announced a proposed issue of 25 million securities, which are options expiring on various dates and at various prices, set to be issued on April 15, 2025. This strategic move is likely to bolster the company’s financial position, potentially enhancing its capacity to further develop its CAR-T therapies and strengthen its market presence in the biotechnology sector.

Chimeric Therapeutics Updates Proposed Securities Issue
Mar 17, 2025

Chimeric Therapeutics Ltd. announced an update to its proposed issue of securities, noting that security holder approval is not required for the issuance of options. The update includes a revised timetable and a minor adjustment to the number of shares and options to be issued, reflecting changes in the shares on issue. This development may streamline the company’s capital raising efforts and potentially enhance its financial flexibility, impacting its strategic positioning in the biotechnology sector.

Chimeric Therapeutics Announces $3.2 Million Entitlement Offer
Mar 17, 2025

Chimeric Therapeutics Ltd. has announced a non-renounceable pro rata entitlement offer to raise approximately $3.2 million through the issuance of new shares and options. The offer includes 2 new shares for every 5 existing shares and 1 new option for each new share issued. Additionally, up to 25 million adviser options will be issued to PAC Partners Securities Pty Ltd and Taylor Collison Limited as joint lead managers. This move is aimed at strengthening the company’s financial position and is considered speculative, indicating potential risks for investors.

Chimeric Therapeutics Launches $3.2 Million Entitlement Offer to Advance Cancer Trials
Mar 17, 2025

Chimeric Therapeutics Limited has announced a non-renounceable entitlement offer to raise approximately $3.2 million. The funds will primarily support the development of their CHM CDH17 Phase 1/2 clinical trial and the CORE-NK program. The offer includes new shares and options at a discounted price, with the proceeds also aiding general working capital and costs associated with the capital raising. This move is expected to enhance Chimeric’s operational capabilities and strengthen its position in the biotechnology sector.

Chimeric Therapeutics Expands Capital with New Share Issuance
Mar 17, 2025

Chimeric Therapeutics Ltd. announced the issuance of 25 million fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) as of March 17, 2025. This move is part of previously announced transactions and is expected to enhance the company’s capital base, potentially supporting its ongoing research and development efforts in the field of cancer therapeutics.

Chimeric Therapeutics to Present at NWR Virtual Healthcare Conference
Mar 12, 2025

Chimeric Therapeutics announced its participation in the NWR Virtual Healthcare Conference, where CEO Dr. Rebecca McQualter will present. This engagement highlights Chimeric’s ongoing efforts to promote its pioneering cell therapy programs, which include advanced clinical trials for their CAR-T and NK cell therapies, potentially enhancing their market presence and stakeholder interest.

Chimeric Therapeutics Resumes Trading with New Entitlement Offer
Mar 4, 2025

Chimeric Therapeutics Ltd. announced the lifting of its trading suspension on the ASX following its decision to conduct an entitlement offer after a previously planned capital raising was not undertaken. This move is expected to impact the company’s financial strategy and market positioning, potentially influencing investor confidence and stakeholder engagement.

Chimeric Therapeutics Announces Proposed Securities Issue to Bolster R&D
Mar 4, 2025

Chimeric Therapeutics Limited announced a proposed issue of securities, involving a standard pro rata issue of 638,059,938 options and ordinary shares. This move is expected to enhance the company’s capital structure, potentially impacting its market position and providing additional resources for its ongoing research and development efforts.

Chimeric Therapeutics Launches $3.2 Million Entitlement Offer to Advance Clinical Trials
Mar 4, 2025

Chimeric Therapeutics has announced an Entitlement Offer to raise approximately $3.2 million, primarily to support the development of its CHM CDH17 Phase 1/2 clinical trial. The offer allows eligible shareholders to purchase new shares at a discounted price, with additional options available, aiding the company’s ongoing clinical developments and strengthening its position in the cell therapy industry.

Chimeric Therapeutics Suspends Trading for Capital Raising Announcement
Mar 3, 2025

Chimeric Therapeutics Limited has requested a voluntary suspension of its securities from the Australian Securities Exchange (ASX) pending an announcement related to a capital raising. The suspension follows a previous trading halt due to the limited availability of investors during the reporting season. This move is anticipated to impact the company’s financial strategy and market operations as it seeks non-dilutionary funding.

Chimeric Therapeutics Reports Increased Losses Amidst Asset Stabilization
Feb 28, 2025

Chimeric Therapeutics Limited reported a significant increase in losses for the half-year ended December 31, 2024, with a 216.9% rise in losses attributable to owners, totaling $2,857,887. Despite the financial setback, the company’s net tangible assets per ordinary security improved from (1.09) cents to (0.35) cents, indicating a potential stabilization in asset valuation. No dividends were declared for the current or previous financial periods, and the company’s financial statements were reviewed with a material uncertainty regarding its going concern status.

Chimeric Therapeutics Secures $4.0m Funding for Innovative Cancer Therapy
Feb 27, 2025

Chimeric Therapeutics has secured approximately A$4.0 million in non-dilutionary funding from a US-based philanthropic family office to advance its CHM CDH17 CAR-T cell therapy. This funding supports the ongoing Phase 1/2 clinical trial aimed at determining the recommended Phase 2 dose and evaluating the safety and response rate in patients with advanced gastrointestinal cancers. The investment underscores the potential of CHM CDH17, a novel therapy targeting CDH17, which is linked to poor prognosis in common gastrointestinal cancers.

Chimeric Therapeutics Expands Capital with ASX Quotation
Feb 12, 2025

Chimeric Therapeutics Limited has announced the quotation of 20 million ordinary fully paid securities on the Australian Securities Exchange (ASX), which forms part of a previously announced transaction. This move is expected to broaden the company’s capital base, potentially enhancing its financial capacity to advance its cancer treatment therapies, thereby potentially impacting its market position and stakeholder interests positively.

Chimeric Therapeutics Issues New Shares to Boost Funding
Feb 11, 2025

Chimeric Therapeutics has announced the issuance of up to 124,888,889 new fully paid ordinary shares to Lind Global Fund II, LP, as part of a share subscription agreement. This move aims to facilitate funding previously advanced by Lind, potentially enhancing the company’s financial stability and market operations.

Chimeric Therapeutics Expands CHM CDH17 Clinical Trial with UChicago Medicine
Feb 9, 2025

Chimeric Therapeutics announced that the University of Chicago Medicine has joined its Phase 1/2 clinical trial for CHM CDH17, a pioneering anti-CDH17 CAR-T cell therapy. This trial targets advanced colorectal, gastric, and intestinal neuroendocrine cancers, with the goal of determining the Phase 2 dose and evaluating safety and response rates. The inclusion of a prestigious institution like UChicago Medicine highlights the potential impact of this therapy on the treatment of gastrointestinal tumors.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.